Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Naturally occurring resorcylic acid lactone as potent and selective MEK inhibitor

Jan. 4, 2000

LY-329146 reverses MRP1- and also P-glycoprotein-associated MDR in cancer cells

Jan. 4, 2000

Retinoids with antineoplastic activity designed at Ligand

Jan. 4, 2000

Antiangiogenic activity of troponin I may involve direct inhibition of bFGF and VEGF receptors

Jan. 3, 2000

Abbott investigates new compounds for angiogenesis-related disorders

Jan. 3, 2000

Immunomedics/IBC develop new fusion protein for use in cancer therapy

Jan. 3, 2000

FDA approves Ligand's Targretin Capsules for treatment of CTCL

Dec. 30, 1999

Warner-Lambert reports R&D progress in the area of kinase inhibitors

Dec. 30, 1999

Antiangiogenic fumagillin analogues in the pipeline at BioChem Pharma

Dec. 29, 1999

Mitsui presents differentiation-inducing agents

Dec. 29, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 14, 2026.
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...